Thomas M Lietman

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Global elimination of trachoma: how frequently should we administer mass chemotherapy?
    T Lietman
    The F I Proctor Foundation and the Department of Ophthalmology, The University of California San Francisco, USA
    Nat Med 5:572-6. 1999
  2. doi request reprint Travel and implications for the elimination of trachoma in ethiopia
    Neelima A Shah
    Department of Public Health Sciences, University of California, Davis, California, USA
    Ophthalmic Epidemiol 17:113-7. 2010
  3. pmc Childhood mortality in a cohort treated with mass azithromycin for trachoma
    Jeremy D Keenan
    F I Proctor Foundation, San Francisco, CA, USA
    Clin Infect Dis 52:883-8. 2011
  4. doi request reprint Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures
    Robert E Fintelmann
    Francis I Proctor Foundation for Research in Ophthalmology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0412, USA
    Arch Ophthalmol 129:399-402. 2011

Research Grants

  1. The Steroids for Cornea Ulcers Trial
    Thomas Lietman; Fiscal Year: 2007
  2. Predicting Resistance: Validating Mathematical Models
    Thomas Lietman; Fiscal Year: 2004
  3. Eliminating trachoma with repeat mass drug treatment
    Thomas Lietman; Fiscal Year: 2007

Collaborators

  • Bruce D Gaynor
  • Paul M Emerson
  • Wondu Alemayehu
  • Jeremy D Keenan
  • Robert E Fintelmann
  • Travis C Porco
  • Neelima A Shah
  • Nisha R Acharya
  • Mulat Zerihun
  • Zhaoxia Zhou
  • Teshome Gebre
  • Vicky Cevallos
  • Eliza N Hoskins
  • Berhan Ayele
  • Jenafir I House
  • Jenafir House
  • John P Whitcher
  • Kevin C Hong
  • Colleen Halfpenny
  • Takele Lakew

Detail Information

Publications4

  1. ncbi request reprint Global elimination of trachoma: how frequently should we administer mass chemotherapy?
    T Lietman
    The F I Proctor Foundation and the Department of Ophthalmology, The University of California San Francisco, USA
    Nat Med 5:572-6. 1999
    ..We recommend, based on our analysis, that in areas where trachoma is moderately prevalent (<35% in children), it should be treated annually, but hyperendemic areas (>50% in children), it should be treated biannually...
  2. doi request reprint Travel and implications for the elimination of trachoma in ethiopia
    Neelima A Shah
    Department of Public Health Sciences, University of California, Davis, California, USA
    Ophthalmic Epidemiol 17:113-7. 2010
    ..Seven hundred and seventeen households with at least one child aged 1-5 years in 48 villages were surveyed to collect the details of travel in 1 month prior to the survey...
  3. pmc Childhood mortality in a cohort treated with mass azithromycin for trachoma
    Jeremy D Keenan
    F I Proctor Foundation, San Francisco, CA, USA
    Clin Infect Dis 52:883-8. 2011
    ..Here, we monitor a large cohort in which almost 90% of individuals received azithromycin. We assess whether receiving treatment is associated with reduced all-cause and infectious childhood mortality...
  4. doi request reprint Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures
    Robert E Fintelmann
    Francis I Proctor Foundation for Research in Ophthalmology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0412, USA
    Arch Ophthalmol 129:399-402. 2011
    ..To determine whether recent use of topical fluoroquinolones is a risk factor for in vitro fluoroquinolone resistance in Staphylococcus aureus ocular isolates...

Research Grants7

  1. The Steroids for Cornea Ulcers Trial
    Thomas Lietman; Fiscal Year: 2007
    ..2) To determine whether the addition of topical steroids results in a higher frequency of adverse outcomes. 3) To determine whether outcomes depend on the organism. ..
  2. Predicting Resistance: Validating Mathematical Models
    Thomas Lietman; Fiscal Year: 2004
    ..3. To test the validity of mathematical models by determining the prevalence of pneumococcal resistance empirically after multiple mass distributions. ..
  3. Eliminating trachoma with repeat mass drug treatment
    Thomas Lietman; Fiscal Year: 2007
    ..To determine whether children form a core group for the transmission of trachoma. Can treatment targeted to children alone eventually eliminate infection in the entire community? ..